Apellis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Apellis Pharmaceuticals has a total shareholder equity of $266.7M and total debt of $93.1M, which brings its debt-to-equity ratio to 34.9%. Its total assets and total liabilities are $831.9M and $565.3M respectively.
Key information
34.9%
Debt to equity ratio
US$93.11m
Debt
Interest coverage ratio | n/a |
Cash | US$333.54m |
Equity | US$266.68m |
Total liabilities | US$565.25m |
Total assets | US$831.93m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1JK's short term assets ($811.4M) exceed its short term liabilities ($215.3M).
Long Term Liabilities: 1JK's short term assets ($811.4M) exceed its long term liabilities ($350.0M).
Debt to Equity History and Analysis
Debt Level: 1JK has more cash than its total debt.
Reducing Debt: 1JK's debt to equity ratio has increased from 3% to 34.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1JK has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1JK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.